Evidence map›Paper›PMID 35247129›Full record

ArticleNeurosurgical review2022

Higher cystatin C level increases the risk of delayed cerebral ischemia after endovascular treatment of aneurysmal subarachnoid hemorrhage: a case-control study.

Kehua Chen, Guanghua Huang, Chengwei Cai, Chuangnan Yan, Fuguang Zhang, Min Yao, Thanana Nuchkrua, Junqiang Ma, Hongwu Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Neurosurgical review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kehua ChenDepartment of Neurosurgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Guanghua HuangShantou University Medical College, Shantou, China.
Chengwei CaiDepartment of Neurosurgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Chuangnan YanDepartment of Neurosurgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Fuguang ZhangDepartment of Neurosurgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Min YaoSchool of Pharmaceutical Sciences, Health Science Centre, Shenzhen University, Shenzhen, China.
Thanana NuchkruaDepartment of Mechanical Engineering, Guangdong Technion-Israel Institute of Technology, Shantou, China.
Junqiang MaDepartment of Neurosurgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, China. 736247781@qq.com.
Hongwu XuDepartment of Neurosurgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, China. hwxu@qq.com.ORCID http://orcid.org/0000-0002-5857-3384
Shantou University · CNGuangdong Technion-Israel Institute of Technology · CNShenzhen University Health Science Center · CN

Funding

the Special Fund for Science and Technology of Guangdong Province [2020]53-50
6 · The paper itself

Abstract

Cystatin C (CysC) has been found to be associated with hemorrhagic and ischemic stroke in many studies. However, the association between CysC level and the risk of delayed cerebral ischemia after endovascular treatment of aneurysmal subarachnoid hemorrhage has been reported rarely. Our study was proposed to explore this association. Consecutive patients from June 2015 to February 2021 in this single-center retrospective study were selected. Univariate and multivariate analyses were used to identify potential prognostic risk factors for delayed cerebral ischemia, and the stability of the association was demonstrated by several statistical methods, such as subgroup analysis, interaction testing, generalized linear models, and propensity score matching. A total of 424 patients were included in the analysis. Cystatin C was independently associated with delayed cerebral ischemia. The independent effects of CysC on delayed cerebral ischemia were shown in generalized linear models with a logit link, and the results were relatively stable in crude, partial, and full models with ORs (95% CIs) for delayed cerebral ischemia. Subgroup analysis showed no significant subgroup differences in the effect of CysC on delayed cerebral ischemia. There was also no interaction effect between CysC and other confounders. Patients in the high CysC group had a higher risk of delayed cerebral ischemia than those in the low CysC group before and after propensity score matching. CysC level could be an independent predictor for the risk of delayed cerebral ischemia after endovascular treatment of aneurysmal subarachnoid hemorrhage.

Indexed as

Brain IschemiaCystatin CSubarachnoid HemorrhageCase-Control StudiesCerebral InfarctionHumansRetrospective StudiesCST3 protein, humanCystatin CAneurysmal subarachnoid hemorrhageCystatin CDelayed cerebral ischemiaEndovascular treatment

Identifiers

PMID35247129
OpenAlexW4220738181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.